Abstract
COVID-19 vaccines have been authorized in multiple countries and more are under rapid development. Careful design of a vaccine prioritization strategy across socio-demographic groups is a crucial public policy challenge given that (1) vaccine supply will be constrained for the first several months of the vaccination campaign, (2) there are stark differences in transmission and severity of impacts from SARS-CoV-2 across groups, and (3) SARS-CoV-2 differs markedly from previous pandemic viruses. We assess the optimal allocation of a limited vaccine supply in the U.S. across groups differentiated by age and also essential worker status, which constrains opportunities for social distancing. We model transmission dynamics using a compartmental model parameterized to capture current understanding of the epidemiological characteristics of COVID-19, including key sources of group heterogeneity (susceptibility, severity, and contact rates). We investigate three alternative policy objectives (minimizing infections, years of life lost, or deaths) and model a dynamic strategy that evolves with the population epidemiological status. We find that this temporal flexibility contributes substantially to public health goals. Older essential workers are typically targeted first. However, depending on the objective, younger essential workers are prioritized to control spread or seniors to directly control mortality. When the objective is minimizing deaths, relative to an untargeted approach, prioritization averts deaths on a range between 20,000 (when non-pharmaceutical interventions are strong) and 300,000 (when these interventions are weak). We illustrate how optimal prioritization is sensitive to several factors, most notably vaccine effectiveness and supply, rate of transmission, and the magnitude of initial infections.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was modeling study an thus clinical trial registration was not applicable.
Funding Statement
This research was supported by an Emergency COVID-19 Seed Award from the California Breast Cancer Research Program of the University of California (UC), Grant Number R00RG2419. GC is partially support by NSF grants #2026797, #2034003, and NIH R01 GM 130900. JB is partailly supported by NSF grant #1650042. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. 1650042. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No human or animal subjects were involved in this study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the article are publicly available from the relevant citation included in the text. Code for the analysis may be obtained from the authors upon request.
